In the claims:

Please amend the claims as follows:

1-75. (Cancelled)

76. (New) A method of treating a patient in need thereof, said method comprising administering an effective amount of protein C or activated protein C polypeptide with a modified GLA domain and an anticoagulant agent, said modified GLA domain comprising three amino acid substitutions at positions selected from the group consisting of residues 10, 11, 28, 32, and 33 of SEQ ID NO: 1.

77. (New) The method of claim 76, wherein said anticoagulant agent is aspirin, warfarin, or heparin.

78. (New) The method of claim 77, wherein said anticoagulant agent is aspirin.

79. (New) A method of treating a patient in need thereof, said method comprising administering an effective amount of protein C or activated protein C polypeptide with a modified GLA domain and an anticoagulant agent, said modified GLA domain comprising three amino acid substitutions at residues 11, 32, and 33 of SEQ ID NO:1.

80. (New) The method of claim 79, wherein residue 32 of SEQ ID NO:1 is glutamic acid and residue 33 of SEQ ID NO:1 is aspartic acid.

81. (New) The method of claim 80, wherein residue 11 of SEQ ID NO:1 is glycine.

82. (New) The method of claim 80, wherein said anticoagulant agent is aspirin, warfarin, or heparin.

83. (New) The method of claim 81, wherein said anticoagulant agent is aspirin, warfarin, or heparin.

84. (New) The method of claim 82, wherein said anticoagulant agent is aspirin.

85. (New) The method of claim 83, wherein said anticoagulant agent is aspirin.

86. (New) A method of treating a patient in need thereof, said method comprising administering an effective amount of activated protein C polypeptide with a modified GLA domain and aspirin, said modified GLA domain comprising three amino acid substitutions at residues 11, 32, and 33 of SEQ ID NO:1, wherein residue 11 of SEQ ID NO:1 is glycine, residue 32 of SEQ ID NO:1 is glutamic acid, and residue 33 of SEQ ID NO:1 is aspartic acid.